10-K: Acrivon Therapeutics 2025 Annual Report Highlights Clinical Progress, Financials

Acrivon Therapeutics' 2025 annual report details significant clinical advancements for its oncology pipeline, including positive interim data for ACR-368 in endometrial cancer and progress for ACR-2316, alongside continued operating losses and a need for future funding.

Summary

• Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision oncology medicines using its proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics (AP3) platform.
• The lead program, ACR-368 (a CHK1/2 inhibitor), is in Phase 2b clinical trials for endometrial cancer (EC), with interim data from the ACR-368-201 trial showing a 39% confirmed Overall Response Rate (ORR) in Arm 1 (OncoSignature-positive EC patients) and 44% in patients treated with 2 prior lines of therapy (pLoT).
• Across pooled OncoSignature-positive and negative subjects with serous EC and 2 pLoT, a confirmed ORR of 52% was observed.
• Two new registrational intent arms (Arm 3 and Arm 4) have been added to the ACR-368-201 study to investigate ACR-368 in biomarker-unselected serous EC subjects, with and without ultra-low dose gemcitabine (ULDG) sensitization, respectively.
• ACR-2316, a novel dual WEE1/PKMYT1 inhibitor, entered Phase 1 clinical development in Q3 2024, two quarters ahead of original timelines, and initial data shows a favorable tolerability profile and clinical activity, including partial responses in EC, SCLC, and sqNSCLC.
• ACR-6840, an internally discovered CDK11 inhibitor, is advancing in IND-enabling studies with a planned IND filing in Q4 2026.
• The company completed and certified an internal CLIA laboratory on February 18, 2026, and subsequently terminated its companion diagnostic agreement with Akoya on February 25, 2026, bringing ACR-368 OncoSignature testing in-house.
• Net loss for the year ended December 31, 2025, was $77.9 million, compared to $80.6 million for 2024, with an accumulated deficit of $274.9 million as of December 31, 2025.
• Cash, cash equivalents, and investments totaled $118.6 million as of December 31, 2025, which is estimated to be sufficient to fund operating expenses and capital expenditure requirements into the second quarter of 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update due to strong interim clinical data for ACR-368 in a high unmet need indication and early positive signs for ACR-2316, coupled with strategic moves to internalize diagnostic capabilities. However, the company remains pre-revenue with substantial future funding needs and faces inherent risks of drug development and market competition.

Positives

• ACR-368 demonstrated a confirmed Overall Response Rate (ORR) of 39% in OncoSignature-positive endometrial cancer (EC) patients in Arm 1 of the ACR-368-201 trial, and 44% in patients treated with 2 prior lines of therapy.
• A high confirmed ORR of 52% was observed in pooled OncoSignature-positive and negative subjects with serous EC (2 prior lines of therapy), an aggressive form of EC.
• ACR-368 showed significant anti-tumor activity and disease control in BM+ patients with aggressive, refractory tumors (33% cORR, 75% DCR) that previously had 0% ORR to the last prior line of therapy.
• ACR-2316 entered clinical development in Q3 2024, two quarters ahead of original timelines, indicating accelerated progress.
• Initial Phase 1 clinical data for ACR-2316 showed a favorable tolerability profile and clinical activity, including partial responses in EC, SCLC, and sqNSCLC, which are tumor types not typically sensitive to other WEE1 or PKMYT1 inhibitors.
• The company completed and certified an internal CLIA laboratory on February 18, 2026, enhancing control and efficiency over diagnostic development.
• The companion diagnostic agreement with Akoya was terminated on February 25, 2026, without financial payments, securing full development and commercialization rights for the ACR-368 OncoSignature test.
• ACR-368 received two Fast Track designations from the FDA on May 8, 2023, for OncoSignature-positive platinum-resistant ovarian cancer and EC.
• The ACR-368 OncoSignature assay was granted Breakthrough Device Designation by the FDA on November 16, 2023, for ovarian cancer, and on January 21, 2025, for EC.
• Net loss decreased to $77.9 million in 2025 from $80.6 million in 2024, indicating a slight improvement in financial performance.
• Existing cash, cash equivalents, and investments of $118.6 million as of December 31, 2025, are projected to fund operations into Q2 2027.

Negatives

• The company has incurred significant losses since its inception, with a net loss of $77.9 million in 2025 and an accumulated deficit of $274.9 million as of December 31, 2025.
• No products have been approved for commercialization, and no revenue has been generated from product sales to date.
• Significant losses and negative cash flows are expected to continue for the foreseeable future.
• Substantial additional funding will be required to continue operations and pursue the growth strategy, as existing capital is only sufficient into Q2 2027.
• The business is highly dependent on the successful clinical development and regulatory approval of ACR-368 and ACR-2316, with no guarantee of approval for any drug candidate.
• Clinical trials are inherently expensive, time-consuming, and unpredictable, with a high risk of failure.
• There is a potential for unexpected adverse side effects or safety risks with drug candidates, which could delay or prevent regulatory approval.
• Reliance on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs) introduces risks related to supply, quality, and regulatory compliance.
• The precision oncology market is highly competitive, with many competitors possessing greater financial resources and expertise.
• Market acceptance of any approved products is uncertain and depends on various factors, including competition, pricing, and reimbursement.
• The company currently lacks an internal marketing and sales organization, requiring significant investment to develop these capabilities.
• Operations are subject to extensive and evolving healthcare laws and regulations, with potential for substantial penalties for non-compliance.
• The company faces an inherent risk of product liability lawsuits, which could result in substantial liabilities.
• Business operations are vulnerable to system failures, cyberattacks, or cybersecurity deficiencies.
• The ability to utilize net operating loss carryforwards and other tax attributes may be limited due to potential ownership changes under Section 382 of the Code.
• Operating as a public company incurs increased costs and demands on management.

Risks

• We have incurred significant losses since our inception and expect to incur losses over the next several years, and may never achieve or maintain profitability.
• We have a limited operating history and no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.
• We will need additional funding to meet our financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned longer-term operations and the pursuit of our growth strategy.
• Our business substantially depends upon the successful clinical development of drug candidates using our AP3 platform and OncoSignature companion diagnostics. If we are unable to obtain regulatory approval for, and successfully commercialize, drugs developed through the application of our AP3 platform and OncoSignature tests, our business may be materially harmed.
• We are highly dependent on the success of ACR-368 and/or ACR-2316, as these are our first drug candidates being developed for clinical development and regulatory approval. We may never obtain approval for ACR-368, ACR-2316, or any other drug candidate.
• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, on a timely basis or at all, our business will be substantially harmed.
• For some of our drug candidates, the successful clinical development may depend on the co-approval of an OncoSignature test as a companion diagnostic test. If we or a companion diagnostic collaborator are unable to obtain regulatory approval for our OncoSignature companion diagnostic tests for such drug candidates, we may not obtain regulatory approval and realize the commercial potential of certain drug candidates.
• Our relationships with customers, healthcare providers, including physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
• Enacted and future legislation may increase the difficulty and cost for us, and any collaborators, to progress our clinical programs and obtain marketing approval or licensure of and commercialize our drug candidates and may affect the prices we, or they, may obtain.
• Even if we are able to commercialize any drug candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.
• We rely, and expect to continue to rely, on third parties, including independent clinical investigators, contracted laboratories and contract research organizations, or CROs, to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.
• The precision oncology space is competitive, which may result in others discovering, developing or commercializing products before or more successfully than we do.
• Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
• Our success depends in part on our ability to obtain intellectual property rights for our proprietary technologies and drug candidates, as well as our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.
• We depend on intellectual property licensed from a third party and termination of this license could result in the loss of significant rights, which would harm our business.
• Preliminary, interim and topline data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and is subject to audit and verification procedures that could result in material changes in the final data.
• Early clinical trials for ACR-2316 may not predict the success of later clinical trials. Furthermore, the results of clinical trials for ACR-2316 may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.
• If we experience delays or difficulties in enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory approval could be delayed or prevented.
• Unexpected adverse side effects or other safety risks associated with ACR-368, ACR-2316, or our other future drug candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials or abandon further development, limit the commercial profile of an approved product or result in significant negative consequences following marketing approval, if any.
• Our clinical development is focused on the development of precision oncology medicines utilizing our proprietary precision medicine platform, which is based on a novel scientific approach and may never lead to marketable products.
• Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CROs, manufacturers, contractors, consultants or collaborators cybersecurity.
• We may not be able to utilize a significant portion of our net operating loss carryforwards and other tax attributes.

Future Outlook

The company expects to incur significant and increasing expenses and operating losses for the foreseeable future as it continues to advance its drug candidates through clinical development, seeks regulatory approval, and pursues potential commercialization. Substantial additional funding will be required beyond the second quarter of 2027. Plans include broadening the pipeline beyond oncology to autoimmune/inflammatory diseases, with the ACR-6840 IND filing planned for Q4 2026 and the initiation of ACR-368-201 Arm 4 in H1 2026. A confirmatory trial combining ACR-368 with anti-PD-1 in first-line EC maintenance is also being planned.

Management Comments

• "Our company name, Acrivon, is derived from Greek for accurate or precise. We chose it to embody how our AP3 platform can, among other highly actionable discovery and development applications, accurately match our therapies with patients who will benefit."
• "By bringing CLIA operations and laboratory resources in-house, we believe that we have gained enhanced capabilities and efficiencies to support the development of its current and future targeted therapeutic agents."

Industry Context

StockSavvy.ai notes that Acrivon Therapeutics operates in the highly competitive precision oncology space, aiming to overcome limitations of genetics-based precision medicine with its phosphoproteomics-based AP3 platform. While the field is expected to eventually recognize proteomics as the "next era of precision medicine," significant competition is anticipated to emerge over the next decade. The company faces competition from major pharmaceutical and biotechnology firms with greater resources, as well as from existing standard-of-care treatments like chemotherapy and radiation. The focus on drug classes where genetics has proven difficult for response prediction positions Acrivon to address a larger fraction of cancer patients, potentially differentiating it from competitors focused solely on genetically-defined cancers.

Comparison to Industry Standards

• ACR-368's confirmed ORR of 39% in BM+ EC patients (35% overall BM+) and 52% in serous EC (pooled BM+/BM-) compares favorably to the 0% ORR observed in the last prior line of therapy for refractory tumors in the trial, indicating a significant improvement over previous treatments for these patients.
• ACR-2316 demonstrated complete tumor regression in preclinical models and initial clinical activity in SCLC and sqNSCLC, two tumor types which have not shown sensitivity to other clinical WEE1 or PKMYT1 inhibitors currently in development, such as adavosertib (Astrazeneca/Merck, discontinued), azenosertib (Zentalis), Debio0123 (Debiopharm), lunresertib (Repare Therapeutics), and SGR-3515 (Schrdinger). This suggests a potentially differentiated therapeutic profile and broader applicability.
• The company's AP3 platform aims to address the 'vast majority of cancers' where genetics-based approaches are insufficient, contrasting with the 'less than 10% of patients' addressed by recently approved precision oncology treatments like kinase inhibitors based on easily-identifiable genetic mutations.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.

Related Party Transactions

• Patent License Agreement with Peter Blume-Jensen (Chief Executive Officer and President), dated April 12, 2018, granted an exclusive, worldwide, irrevocable, perpetual, royalty-free license under certain licensed patents relating to broad aspects of the general discovery process for biomarkers in OncoSignature tests. As consideration, 871,857 shares of common stock were issued to Dr. Blume-Jensen, and $150,000 was reimbursed for past expenses in October 2020.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity offerings; stock price volatility influenced by clinical trial outcomes and market perception; influence of executive officers, directors, and principal stockholders on corporate decisions.
• Patients: Potential for new precision oncology treatments for high unmet clinical needs (e.g., EC, SCLC, sqNSCLC); improved treatment outcomes through the OncoSignature patient selection method.
• Employees: Continued growth in headcount, particularly in research and development; potential for increased compensation (salaries, bonuses, stock-based compensation); exposure to strict insider trading policies and potential for disciplinary action for non-compliance.
• Partners/Collaborators: Existing partnerships (e.g., Lilly) and potential for new strategic collaborations; risks associated with partner performance and intellectual property disputes, as seen with the Akoya agreement termination.
• Regulatory Bodies: Ongoing compliance with FDA and foreign regulatory requirements; impact of evolving regulations (e.g., master protocols, LDTs, IRA, APA ruling) on drug development and approval timelines and costs.

Next Steps

• Expand ACR-368-201 Arm 3 (serous EC, all-comer, with ULDG) to over 20 sites in 4 major EU countries (Italy, Spain, Germany, France).
• Initiate ACR-368-201 Arm 4 (serous EC, all-comer, monotherapy) in H1 2026.
• Plan a confirmatory trial combining ACR-368 with anti-PD-1 vs anti-PD-1 in the maintenance phase of first-line therapy for EC.
• Conduct additional preclinical and clinical evaluations to further assess the synergistic potential of ACR-368 in combination regimens, particularly with topoisomerase inhibitors in ADCs.
• Advance ACR-6840 (CDK11 inhibitor) in IND-enabling studies for planned IND filing in Q4 2026.
• Initiate a cohort for ACR-2316 aiming to establish a bi-weekly 2d on / 12d off dosing regimen.
• Potentially study ACR-368 in additional tumor types, such as myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN).
• Strategically evaluate target/compound validation and indication finding opportunities for a new program in autoimmune/inflammatory diseases leveraging AP3.
• Continue to develop and update policies and procedures in accordance with requirements under applicable data privacy and protection laws and regulations.

Key Dates

Recommendation

Acrivon Therapeutics shows promising early clinical data for ACR-368 and ACR-2316, particularly in difficult-to-treat cancers, and has strengthened its diagnostic capabilities by bringing CLIA operations in-house. These are significant positive developments. However, the company remains in a clinical stage, is pre-revenue, and continues to incur substantial losses, necessitating significant additional funding by Q2 2027. The inherent risks of drug development, regulatory uncertainties, and intense competition warrant a cautious approach. A "hold" recommendation reflects the potential upside from clinical success balanced against the considerable financial and operational risks.

Keywords

Precision Oncology, Biopharmaceutical, Drug Development, Clinical Trials, ACR-368, ACR-2316, AP3 Platform, OncoSignature, Endometrial Cancer, CHK1/2 Inhibitor, WEE1/PKMYT1 Inhibitor, Biomarkers, Companion Diagnostics, Biotechnology, Cancer Treatment, Drug Discovery, Regulatory Approval, Financial Reporting, SEC Filing, 10-K